CHRS Coherus BioSciences Inc
Price (delayed)
$1.03
Market cap
$119.37M
P/E Ratio
4.12
Dividend/share
N/A
EPS
$0.25
Enterprise value
$261.6M
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings
Highlights
The net income has soared by 112% YoY
Coherus BioSciences's EPS has surged by 110% YoY
The equity has plunged by 50% from the previous quarter but it has grown by 32% YoY
The revenue has declined by 12% since the previous quarter but it rose by 3.8% year-on-year
Coherus BioSciences's quick ratio has decreased by 23% YoY and by 12% QoQ
Key stats
What are the main financial stats of CHRS
Market
Valuations
Earnings
Shares outstanding
115.9M
Market cap
$119.37M
Enterprise value
$261.6M
Price to earnings (P/E)
4.12
Price to book (P/B)
N/A
Price to sales (P/S)
0.44
EV/EBIT
4.7
EV/EBITDA
4.2
EV/Sales
0.98
Revenue
$266.96M
Gross profit
$149.41M
Operating income
-$111.67M
Net income
$28.51M
EBIT
$55.67M
EBITDA
$62.34M
Free cash flow
-$20.44M
Per share
Balance sheet
Liquidity
EPS
$0.25
EPS diluted
$0.25
Free cash flow per share
-$0.18
Book value per share
-$1.15
Revenue per share
$2.33
TBVPS
$3.45
Total assets
$448.53M
Total liabilities
$580.52M
Debt
$268.21M
Equity
-$131.99M
Working capital
$58.6M
Debt to equity
-2.03
Current ratio
1.21
Quick ratio
0.88
Net debt/EBITDA
2.28
Margins
Efficiency
Dividend
EBITDA margin
23.3%
Gross margin
56%
Net margin
10.7%
Operating margin
-41.8%
Return on assets
4.8%
Return on equity
N/A
Return on invested capital
18.1%
Return on capital employed
33.6%
Return on sales
20.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CHRS stock price
How has the Coherus BioSciences stock price performed over time
Intraday
0%
1 week
-2.83%
1 month
22.82%
1 year
-49.51%
YTD
-25.36%
QTD
27.63%
Financial performance
How have Coherus BioSciences's revenue and profit performed over time
Revenue
$266.96M
Gross profit
$149.41M
Operating income
-$111.67M
Net income
$28.51M
Gross margin
56%
Net margin
10.7%
The net margin has soared by 112% year-on-year
The net income has soared by 112% YoY
The gross profit has soared by 52% YoY and by 10% from the previous quarter
The company's operating margin rose by 47% YoY and by 8% QoQ
Growth
What is Coherus BioSciences's growth rate over time
Valuation
What is Coherus BioSciences stock price valuation
P/E
4.12
P/B
N/A
P/S
0.44
EV/EBIT
4.7
EV/EBITDA
4.2
EV/Sales
0.98
Coherus BioSciences's EPS has surged by 110% YoY
The equity has plunged by 50% from the previous quarter but it has grown by 32% YoY
The P/S is 80% below the 5-year quarterly average of 2.2 and 27% below the last 4 quarters average of 0.6
The revenue has declined by 12% since the previous quarter but it rose by 3.8% year-on-year
Efficiency
How efficient is Coherus BioSciences business performance
CHRS's return on invested capital has surged by 162% year-on-year and by 123% since the previous quarter
Coherus BioSciences's return on sales has surged by 127% YoY and by 99% QoQ
The return on assets has surged by 111% year-on-year
Dividends
What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CHRS.
Financial health
How did Coherus BioSciences financials performed over time
The total assets is 23% less than the total liabilities
The total assets has contracted by 29% YoY and by 11% from the previous quarter
The company's total liabilities fell by 29% YoY and by 2.1% QoQ
The equity has plunged by 50% from the previous quarter but it has grown by 32% YoY
The debt has declined by 44% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.